The European Conference of Infection and Leukemia, ECIL, is an organization founded by several societies, including EBMT as being one of the founding fathers of the organization. We have made guidelines for many different topics over now almost 20 years, and this is the third edition of the CMV guidelines. The CMV guidelines will be published in Lancet Infectious Diseases the day after this meeting ends, meaning on Thursday, and I presented those guidelines in my talk here...
The European Conference of Infection and Leukemia, ECIL, is an organization founded by several societies, including EBMT as being one of the founding fathers of the organization. We have made guidelines for many different topics over now almost 20 years, and this is the third edition of the CMV guidelines. The CMV guidelines will be published in Lancet Infectious Diseases the day after this meeting ends, meaning on Thursday, and I presented those guidelines in my talk here.
Basically, it gives an update on mainly prevention of CMV complications, but also how to monitor patients and treatment of more complicated CMV. Another new aspect in prevention is that we expect the most used prophylactic drug, letermovir, to be approved for children within the EU in the next couple of weeks. It is on the table of the European Commission for decision at this time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
